<DOC>
	<DOCNO>NCT00301028</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Drugs use chemotherapy , carboplatin , paclitaxel , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray type radiation kill tumor cell . Giving cetuximab together combination chemotherapy radiation therapy , without cisplatin , may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together carboplatin paclitaxel follow radiation therapy , without cisplatin , work treat patient metastatic head neck cancer .</brief_summary>
	<brief_title>Cetuximab , Carboplatin , Paclitaxel Followed Radiation Therapy , With Without Cisplatin , Treating Patients With Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine increase clinical/radiographic complete response rate patient previously untreated metastatic squamous cell carcinoma head neck treat induction therapy comprise cetuximab , carboplatin , paclitaxel . - Determine toxic effect regimen patient . Secondary - Determine pattern tumor recurrence patient treat regimen . - Determine quality life patient treat regimen . - Determine duration response , time progression , survival patient treat regimen . - Correlate effect regimen biomarkers response predictor long-term outcome patient . OUTLINE : This nonrandomized , open-label study . Patients receive induction therapy comprise cetuximab IV 1-2 hour , paclitaxel IV 1 hour , carboplatin IV 1 hour day 1 . Treatment repeat weekly 6 course absence disease progression unacceptable toxicity . Beginning 2-3 week later , patient undergo radiotherapy chemoradiotherapy . Patients T0 , 1 , 2 disease undergo radiotherapy 5 day week 6 week . Patients T3 , 4 disease unresectable nodal disease undergo radiotherapy 5 day week 6 week receive concurrent cisplatin IV 1-2 hour day 1 22 . Some patient may undergo primary surgical resection instead radiotherapy chemoradiotherapy . Quality life assess baseline 6 , 12 , 24 month completion radiotherapy surgery . After study completion , patient follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 80 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patients histological proof ( primary lesion and/or lymph node ) squamous cell carcinoma oral cavity , oropharynx , nasopharynx , hypopharynx , larynx . 2 . Patients stage IV disease , stage T04 N2b/2c/3 M0 ( nasopharynx patient , stage N1 disease eligible ) . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) require . 3 . Patients stage Tx primary disease eligible N2b/3 adenopathy . 4 . Karnofsky performance status &gt; /= 80 Eastern Cooperative Oncology Group ( ECOG ) point scale 01 5 . Age &gt; 16 year 6 . Patients adequate bone marrow function define absolute peripheral granulocyte count ( AGC ) &gt; 1500 cells/mm3 platelet count &gt; 100,000 cells/mm3 ; adequate hepatic function bilirubin &lt; /= Upper Limit Normal ( ULN ) , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) may 2.5 time upper limit normal alkaline phosphatase normal . Alkaline phosphatase may 4* ULN SGPT SGOT normal . Patients SGPT SGOT &gt; 1.5 ULN alkaline phosphatase &gt; 2.5 * ULN eligible . Normal PT/PTT normal serum calcium ( without intervention ) require . 7 . Creatinine clearance &gt; 40 ml/min determine 24 hour collection nomogram : CrCl male = ( 140 age ) time ( weight kg ) /serum Cr time 72 CrCl female = 0.85 time ( CrCl male ) 8 . Patients serious acute chronic comorbid condition , acute infection . 9 . Patients must sign studyspecific inform consent form . 1 . Histology squamous cell carcinoma . 2 . Evidence distant metastasis ( clavicle ) clinical radiographic mean . 3 . Karnofsky performance status &lt; 80 ECOG &gt; 1 4 . Prior chemotherapy , within previous 3 year . 5 . Prior radiotherapy head neck . 6 . Prior cetuximab therapy , prior therapy drug target EGFR pathway , prior therapy murine chimeric monoclonal antibody . 7 . Initial surgical resection render patient clinically radiologically disease free . 8 . Simultaneous primary invasive cancer . 9 . Patients another malignancy ( exclude non melanoma skin cancer , cancer treat &gt; 3 year prior patient remain continuously disease free ) . 10 . Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . Subjects men must also agree use effective contraception . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ( HCG ) ) within 72 hour prior start study medication . 11 . WOCBP use prohibit contraceptive method . 12 . Women pregnant breastfeeding . 13 . Women positive pregnancy test enrollment prior study drug administration . 14 . Refusal sign inform consent . 15 . Preexisting peripheral neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 worse .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
</DOC>